about
The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.Increased expression of Fibrinogen-Like Protein 2 is associated with poor prognosis in patients with clear cell renal cell carcinoma.Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression.A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy.Clinical outcomes of the sequential use of pazopanib followed by everolimus for the treatment of metastatic renal cell carcinoma: a multicenter study in Korea.miRNAs as potential regulators of mTOR pathway in renal cell carcinoma.Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study.Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL-deficient human renal cell carcinoma.Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.LncRNA LOC653786 promotes growth of RCC cells via upregulating FOXM1.A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma.Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells.Quantification of sarcomatoid differentiation in renal cell carcinoma on magnetic resonance imaging.Epidemiology and screening for renal cancer
P2860
Q33591361-BF45EE92-9948-48A7-8920-E299F9823D90Q41573990-BF292FA7-FF68-4501-B480-91F64698E981Q42045274-AF0988E7-32CF-4D77-8EA4-B7944C7D322FQ47115184-A9FAE42D-1B1F-4164-9F9A-2EFB93090AC5Q47140629-288FE806-63B6-4D89-B2A7-B1AAD1A8A73EQ47417154-088295C8-48E1-415C-ABEC-AF196EEB3A7DQ47553641-6B511E64-78B6-4DD8-BE8F-E70D3E15D7C9Q47737549-56029B6A-9F1D-4298-B39D-A612A38409BFQ48096443-F5560602-BB2C-4A3D-A066-58CFD5295366Q48256655-A647213F-B249-4EFA-AB8F-CBB7A3E5AFD7Q49405081-15F12AF9-6AB1-4B5E-AEFA-A45CF2A115CBQ50053294-D9F7BF3A-E964-4180-84E2-5467C1439F50Q52649603-30A8E353-E13C-4BE0-9D88-B3AA234DA164Q53186440-7B10F2EB-78AD-48EF-8FCB-D290D8A9F457Q54112994-A2A94E72-CC14-47AB-9C62-9C6D7395CE28Q55327529-43BDC130-1002-4EAF-BAA3-E2EB28D508DFQ57640122-090CE8B3-6AC2-490B-8589-A88E8A9BE58E
P2860
description
im Juni 2016 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 09 June 2016
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2017
@uk
name
Systemic therapy in metastatic renal cell carcinoma
@en
Systemic therapy in metastatic renal cell carcinoma
@nl
type
label
Systemic therapy in metastatic renal cell carcinoma
@en
Systemic therapy in metastatic renal cell carcinoma
@nl
prefLabel
Systemic therapy in metastatic renal cell carcinoma
@en
Systemic therapy in metastatic renal cell carcinoma
@nl
P2093
P2860
P1476
Systemic therapy in metastatic renal cell carcinoma
@en
P2093
Axel Hegele
Edwin Herrmann
Hans Tesch
Jan Janssen
Kurt Miller
Martin Schostak
Stefan Hinz
Stefan Zastrow
Stephan Schmitz
Thomas Gauler
P2860
P2888
P304
P356
10.1007/S00345-016-1868-5
P407
P50
P5008
P577
2016-06-09T00:00:00Z